Nephron implements automated microbial testing tool

Listen to this article

Nephron Pharmaceuticals Corp., headquartered in West Columbia, has announced the implementation of a microbial testing tool that the generic respiratory medication manufacturer says will help it deliver medical supplies to hospitals faster than ever.

Growth Direct, developed by Massachusetts-based lab equipment supplier Rapid Micro Biosystems, automates the incubation, colony counting and data entry of microbial environment testing, according to a Nephron news release. The tool also detects microbial growth 50% faster than human eye.

“We work hard, day in and out, to deliver safe, effective and affordable life-saving medications as efficiently as possible,” Nephron CEO Lou Kennedy said in the release. “Automating our microbial monitoring process allows us to produce safer drugs faster and decreases the shortage of opioid-free pain medication currently facing our nation’s hospitals.”

Growth Direct will allow Nephron’s 503(b) outsourcing division, which produces pre-filled sterile syringes and IV bags, to deliver medical supplies more quickly, the release said.

“We're excited that Nephron Pharmaceuticals Corp. has joined the growing list of global pharmaceutical manufacturers who are upgrading and automating their QC Microbial testing methods with the Growth Direct,” Rapid Micro Biosystems CEO Rob Spignesi said. “And we are proud to help Nephron Pharmaceuticals reduce the shortage of important drugs that help make surgery safer and less painful for patients across the country.”